As of the latest Form 4 filed Jun 10, 2026.
What Laboratory Corporation of America Holdings insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 133 most recent filings for LH.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-10 | 2026-06-08 | Kyle Kathryn W EVP, Chief Legal Officer | SSale | −762.00 | $263.89 | $201K | Yes (planned) | Form 4 ↗ |
| 2026-05-13 | 2026-05-11 | Schechter Adam H President & CEO | SSale | −5.90K | $254.50 | $1.50M | Yes (planned) | Form 4 ↗ |
| 2026-03-30 | 2026-03-27 | Wilkinson Peter J SVP, Chief Accounting Officer | SSale | −1.63K | $267.05 | $436K | Yes (planned) | Form 4 ↗ |
| 2026-03-30 | 2026-03-27 | Meltzer Jonathan C EVP, Operations | SSale | −839.00 | $267.05 | $224K | Yes (planned) | Form 4 ↗ |
| 2026-03-30 | 2026-03-26 | Schechter Adam H President & CEO | FTax | −26.1K | $268.38 | $7.01M | No | Form 4 ↗ |
| 2026-03-30 | 2026-03-26 | Schechter Adam H, President & CEO | AAward | +58.5K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-30 | 2026-03-26 | GRAHAM ANITA Z EVP, CHRO | FTax | −2.88K | $268.38 | $773K | No | Form 4 ↗ |
| 2026-03-30 | 2026-03-26 | GRAHAM ANITA Z, EVP, CHRO | AAward | +6.60K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-30 | 2026-03-26 | Schroeder Mark S EVP, Pres Diagnostics & COO | FTax | −1.47K | $268.38 | $394K | No | Form 4 ↗ |
| 2026-03-30 | 2026-03-26 | Schroeder Mark S, EVP, Pres Diagnostics & COO | AAward | +2.97K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-30 | 2026-03-26 | Schroeder Mark S, EVP, Pres Diagnostics & COO | FTax | −4.60K | $268.38 | $1.23M | No | Form 4 ↗ |
| 2026-03-30 | 2026-03-26 | Schroeder Mark S, EVP, Pres Diagnostics & COO | AAward | +9.30K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-30 | 2026-03-26 | Caveney Brian J EVP, Pres of ED, CMO & CSO | FTax | −863.00 | $268.38 | $232K | No | Form 4 ↗ |
| 2026-03-30 | 2026-03-26 | Caveney Brian J, EVP, Pres of ED, CMO & CSO | AAward | +1.99K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-30 | 2026-03-26 | Caveney Brian J, EVP, Pres of ED, CMO & CSO | FTax | −4.04K | $268.38 | $1.08M | No | Form 4 ↗ |
| 2026-03-30 | 2026-03-26 | Caveney Brian J, EVP, Pres of ED, CMO & CSO | AAward | +9.30K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-30 | 2026-03-26 | Wilkinson Peter J SVP, Chief Accounting Officer | FTax | −755.00 | $268.38 | $203K | Yes (planned) | Form 4 ↗ |
| 2026-03-30 | 2026-03-26 | Wilkinson Peter J, SVP, Chief Accounting Officer | AAward | +2.39K | $0.00 | $0.00 | Yes (planned) | Form 4 ↗ |
| 2026-03-30 | 2026-03-26 | Vaughn Bryan T EVP, Diagnostics | FTax | −451.00 | $268.38 | $121K | No | Form 4 ↗ |
| 2026-03-30 | 2026-03-26 | Vaughn Bryan T, EVP, Diagnostics | AAward | +1.58K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-30 | 2026-03-26 | van der Vaart Sandra D EVP, Corporate Affairs | FTax | −2.72K | $268.38 | $731K | No | Form 4 ↗ |
| 2026-03-30 | 2026-03-26 | van der Vaart Sandra D, EVP, Corporate Affairs | AAward | +6.38K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-30 | 2026-03-26 | Summy Amy B. EVP, Chief Marketing Officer | FTax | −1.84K | $268.38 | $493K | No | Form 4 ↗ |
| 2026-03-30 | 2026-03-26 | Summy Amy B., EVP, Chief Marketing Officer | AAward | +3.99K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-30 | 2026-03-26 | Oyegunwa Akinbolade EVP, CIO & CTO | FTax | −382.00 | $268.38 | $103K | No | Form 4 ↗ |
| 2026-03-30 | 2026-03-26 | Oyegunwa Akinbolade, EVP, CIO & CTO | AAward | +1.34K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-30 | 2026-03-26 | Meltzer Jonathan C EVP, Operations | FTax | −711.00 | $268.38 | $191K | Yes (planned) | Form 4 ↗ |
| 2026-03-30 | 2026-03-26 | Meltzer Jonathan C, EVP, Operations | AAward | +2.39K | $0.00 | $0.00 | Yes (planned) | Form 4 ↗ |
| 2026-03-30 | 2026-03-26 | Kyle Kathryn W EVP, Chief Legal Officer | FTax | −451.00 | $268.38 | $121K | No | Form 4 ↗ |
| 2026-03-30 | 2026-03-26 | Kyle Kathryn W, EVP, Chief Legal Officer | AAward | +1.58K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-03-30 | 2026-03-26 | Bailey Megan D. EVP, Pres, Central Labs & Intl | FTax | −481.00 | $268.38 | $129K | No | Form 4 ↗ |
| 2026-03-30 | 2026-03-26 | Bailey Megan D., EVP, Pres, Central Labs & Intl | AAward | +1.18K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-02-26 | 2026-02-24 | Caveney Brian J EVP, Pres of ED, CMO & CSO | SSale | −1.50K | $286.31 | $429K | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-12 | Meltzer Jonathan C EVP, Operations | SSale | −87.00 | $290.42 | $25.3K | Yes (planned) | Form 4 ↗ |
| 2026-02-13 | 2026-02-11 | Summy Amy B. EVP, Chief Marketing Officer | FTax | −83.00 | $289.89 | $24.1K | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-11 | Summy Amy B., EVP, Chief Marketing Officer | MExercise | +230.00 | — | — | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-11 | Wilkinson Peter J SVP, Chief Accounting Officer | FTax | −46.00 | $289.89 | $13.3K | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-11 | Wilkinson Peter J, SVP, Chief Accounting Officer | MExercise | +160.00 | — | — | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-11 | Wilkinson Peter J, SVP, Chief Accounting Officer | FTax | −160.00 | $289.89 | $46.4K | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-11 | Wilkinson Peter J, SVP, Chief Accounting Officer | MExercise | +536.00 | — | — | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-11 | Wang Julia Aijun Chief Financial Officer, EVP | FTax | −245.00 | $289.89 | $71.0K | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-11 | Wang Julia Aijun, Chief Financial Officer, EVP | MExercise | +860.00 | — | — | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-11 | Vaughn Bryan T EVP, Diagnostics | FTax | −93.00 | $289.89 | $27.0K | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-11 | Vaughn Bryan T, EVP, Diagnostics | MExercise | +323.00 | — | — | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-11 | van der Vaart Sandra D EVP, Corporate Affairs | FTax | −99.00 | $289.89 | $28.7K | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-11 | van der Vaart Sandra D, EVP, Corporate Affairs | MExercise | +376.00 | — | — | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-11 | Schroeder Mark S EVP, Pres Diagnostics & COO | FTax | −259.00 | $289.89 | $75.1K | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-11 | Schroeder Mark S, EVP, Pres Diagnostics & COO | MExercise | +806.00 | — | — | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-11 | Schechter Adam H President & CEO | FTax | −1.52K | $289.89 | $441K | Yes (planned) | Form 4 ↗ |
| 2026-02-13 | 2026-02-11 | Schechter Adam H, President & CEO | MExercise | +3.66K | — | — | Yes (planned) | Form 4 ↗ |
| 2026-02-13 | 2026-02-11 | Schechter Adam H, President & CEO | SSale | −5.27K | $284.38 | $1.50M | Yes (planned) | Form 4 ↗ |
| 2026-02-13 | 2026-02-11 | Oyegunwa Akinbolade EVP, CIO & CTO | FTax | −68.00 | $289.89 | $19.7K | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-11 | Oyegunwa Akinbolade, EVP, CIO & CTO | MExercise | +230.00 | — | — | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-11 | Meltzer Jonathan C EVP, Operations | FTax | −70.00 | $289.89 | $20.3K | Yes (planned) | Form 4 ↗ |
| 2026-02-13 | 2026-02-11 | Meltzer Jonathan C, EVP, Operations | MExercise | +243.00 | — | — | Yes (planned) | Form 4 ↗ |
| 2026-02-13 | 2026-02-11 | Kyle Kathryn W EVP, Chief Legal Officer | FTax | −62.00 | $289.89 | $18.0K | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-11 | Kyle Kathryn W, EVP, Chief Legal Officer | MExercise | +216.00 | — | — | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-11 | GRAHAM ANITA Z EVP, CHRO | FTax | −109.00 | $289.89 | $31.6K | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-11 | GRAHAM ANITA Z, EVP, CHRO | MExercise | +356.00 | — | — | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-11 | Caveney Brian J EVP, Pres of ED, CMO & CSO | FTax | −211.00 | $289.89 | $61.2K | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-11 | Caveney Brian J, EVP, Pres of ED, CMO & CSO | MExercise | +740.00 | — | — | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-11 | Bailey Megan D. EVP, Pres, Central Labs & Intl | FTax | −138.00 | $289.89 | $40.0K | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-11 | Bailey Megan D., EVP, Pres, Central Labs & Intl | MExercise | +403.00 | — | — | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-11 | Rothman Paul Director | MExercise | +897.00 | — | — | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-11 | Wengel Kathryn E Director | MExercise | +897.00 | — | — | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-11 | Parham Richelle P Director | MExercise | +897.00 | — | — | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-11 | NEUPERT PETER M Director | MExercise | +897.00 | — | — | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-11 | Kong Garheng Director | MExercise | +897.00 | — | — | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-11 | Kliphouse Kirsten Marie Director | MExercise | +897.00 | — | — | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-11 | Davis Jeffrey A. Director | MExercise | +897.00 | — | — | No | Form 4 ↗ |
| 2026-02-13 | 2026-02-11 | ANDERSON KERRII B Director | MExercise | +897.00 | — | — | No | Form 4 ↗ |
| 2026-02-12 | 2026-02-10 | Meltzer Jonathan C EVP, Operations | SSale | −91.00 | $276.79 | $25.2K | Yes (planned) | Form 4 ↗ |
| 2026-02-10 | 2026-02-09 | Caveney Brian J EVP, Pres of ED, CMO & CSO | FTax | −32.00 | $274.01 | $8.77K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-09 | Caveney Brian J, EVP, Pres of ED, CMO & CSO | FTax | −148.00 | $274.01 | $40.6K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-09 | Oyegunwa Akinbolade EVP, CIO & CTO | FTax | −51.00 | $274.01 | $14.0K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-09 | Schechter Adam H President & CEO | FTax | −1.35K | $274.01 | $370K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-09 | Wilkinson Peter J SVP, Chief Accounting Officer | FTax | −46.00 | $274.01 | $12.6K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-09 | Schroeder Mark S EVP, Pres Diagnostics & COO | FTax | −53.00 | $274.01 | $14.5K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-09 | Schroeder Mark S, EVP, Pres Diagnostics & COO | FTax | −166.00 | $274.01 | $45.5K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-09 | van der Vaart Sandra D EVP, Corporate Affairs | FTax | −93.00 | $274.01 | $25.5K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-09 | Vaughn Bryan T EVP, Diagnostics | FTax | −61.00 | $274.01 | $16.7K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-09 | Meltzer Jonathan C EVP, Operations | FTax | −82.00 | $274.01 | $22.5K | Yes (planned) | Form 4 ↗ |
| 2026-02-10 | 2026-02-09 | Meltzer Jonathan C, EVP, Operations | SSale | −88.00 | $275.53 | $24.2K | Yes (planned) | Form 4 ↗ |
| 2026-02-10 | 2026-02-09 | Kyle Kathryn W EVP, Chief Legal Officer | FTax | −61.00 | $274.01 | $16.7K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-09 | GRAHAM ANITA Z EVP, CHRO | FTax | −112.00 | $274.01 | $30.7K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-09 | Summy Amy B. EVP, Chief Marketing Officer | FTax | −80.00 | $274.01 | $21.9K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-09 | Bailey Megan D. EVP, Pres, Central Labs & Intl | FTax | −23.00 | $274.01 | $6.30K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-09 | Bailey Megan D., EVP, Pres, Central Labs & Intl | FTax | −85.00 | $274.01 | $23.3K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-07 | Caveney Brian J EVP, Pres of ED, CMO & CSO | MExercise | +111.00 | — | — | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-07 | Caveney Brian J, EVP, Pres of ED, CMO & CSO | MExercise | +517.00 | — | — | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-07 | Oyegunwa Akinbolade EVP, CIO & CTO | MExercise | +149.00 | — | — | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-07 | Schechter Adam H President & CEO | MExercise | +3.25K | — | — | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-07 | Wilkinson Peter J SVP, Chief Accounting Officer | MExercise | +134.00 | — | — | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-07 | Schroeder Mark S EVP, Pres Diagnostics & COO | MExercise | +164.00 | — | — | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-07 | Schroeder Mark S, EVP, Pres Diagnostics & COO | MExercise | +517.00 | — | — | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-07 | van der Vaart Sandra D EVP, Corporate Affairs | MExercise | +353.00 | — | — | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-07 | Vaughn Bryan T EVP, Diagnostics | MExercise | +178.00 | — | — | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-07 | Meltzer Jonathan C EVP, Operations | MExercise | +263.00 | — | — | Yes (planned) | Form 4 ↗ |
| 2026-02-10 | 2026-02-07 | Kyle Kathryn W EVP, Chief Legal Officer | MExercise | +178.00 | — | — | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-07 | GRAHAM ANITA Z EVP, CHRO | MExercise | +367.00 | — | — | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-07 | Summy Amy B. EVP, Chief Marketing Officer | MExercise | +222.00 | — | — | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-07 | Bailey Megan D. EVP, Pres, Central Labs & Intl | MExercise | +67.00 | — | — | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-07 | Bailey Megan D., EVP, Pres, Central Labs & Intl | MExercise | +222.00 | — | — | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Wang Julia Aijun Chief Financial Officer, EVP | FTax | −254.00 | $277.20 | $70.4K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Wang Julia Aijun, Chief Financial Officer, EVP | MExercise | +893.00 | — | — | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Caveney Brian J EVP, Pres of ED, CMO & CSO | FTax | −209.00 | $277.20 | $57.9K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Caveney Brian J, EVP, Pres of ED, CMO & CSO | MExercise | +670.00 | — | — | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Oyegunwa Akinbolade EVP, CIO & CTO | FTax | −61.00 | $277.20 | $16.9K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Oyegunwa Akinbolade, EVP, CIO & CTO | MExercise | +180.00 | — | — | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Schechter Adam H President & CEO | FTax | −1.31K | $277.20 | $365K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Schechter Adam H, President & CEO | MExercise | +4.46K | — | — | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Wilkinson Peter J SVP, Chief Accounting Officer | FTax | −45.00 | $277.20 | $12.5K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Wilkinson Peter J, SVP, Chief Accounting Officer | MExercise | +133.00 | — | — | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Schroeder Mark S EVP, Pres Diagnostics & COO | FTax | −239.00 | $277.20 | $66.3K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Schroeder Mark S, EVP, Pres Diagnostics & COO | MExercise | +743.00 | — | — | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | van der Vaart Sandra D EVP, Corporate Affairs | FTax | −101.00 | $277.20 | $28.0K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | van der Vaart Sandra D, EVP, Corporate Affairs | MExercise | +387.00 | — | — | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Vaughn Bryan T EVP, Diagnostics | FTax | −61.00 | $277.20 | $16.9K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Vaughn Bryan T, EVP, Diagnostics | MExercise | +180.00 | — | — | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Meltzer Jonathan C EVP, Operations | FTax | −91.00 | $277.20 | $25.2K | Yes (planned) | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Meltzer Jonathan C, EVP, Operations | MExercise | +267.00 | — | — | Yes (planned) | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Kyle Kathryn W EVP, Chief Legal Officer | FTax | −61.00 | $277.20 | $16.9K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Kyle Kathryn W, EVP, Chief Legal Officer | MExercise | +180.00 | — | — | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | GRAHAM ANITA Z EVP, CHRO | FTax | −119.00 | $277.20 | $33.0K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | GRAHAM ANITA Z, EVP, CHRO | MExercise | +327.00 | — | — | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Summy Amy B. EVP, Chief Marketing Officer | FTax | −92.00 | $277.20 | $25.5K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Summy Amy B., EVP, Chief Marketing Officer | MExercise | +223.00 | — | — | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Bailey Megan D. EVP, Pres, Central Labs & Intl | FTax | −72.00 | $277.20 | $20.0K | No | Form 4 ↗ |
| 2026-02-10 | 2026-02-06 | Bailey Megan D., EVP, Pres, Central Labs & Intl | MExercise | +180.00 | — | — | No | Form 4 ↗ |
| 2024-05-02 | 2024-05-02 | ANDERSON KERRII B Director | SSale | −250.00 | $200.10 | $50.0K | No | Form 4 ↗ |
| 2024-05-02 | 2024-04-30 | ANDERSON KERRII B, Director | SSale | −250.00 | $204.14 | $51.0K | No | Form 4 ↗ |
| 2024-05-02 | 2024-04-30 | EISENBERG GLENN A Chief Financial Officer, EVP | FTax | −4.50K | $201.37 | $905K | No | Form 4 ↗ |
| 2024-05-02 | 2024-04-30 | EISENBERG GLENN A, Chief Financial Officer, EVP | MExercise | +10.2K | — | — | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also LH’s full analysis or the market-wide insider trading feed. The tabs above jump to LH’s other SEC data.
Source: SEC Form 4 filings for LH, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.